HC Wainwright Has Bearish Forecast for ONCY Q2 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Equities research analysts at HC Wainwright decreased their Q2 2026 earnings per share (EPS) estimates for Oncolytics Biotech in a research report issued to clients and investors on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.07) for the quarter, down from their previous forecast of ($0.03). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.28) EPS, Q1 2027 earnings at ($0.04) EPS, Q2 2027 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at ($0.03) EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at ($0.14) EPS and FY2029 earnings at ($0.12) EPS.

ONCY has been the subject of a number of other reports. Weiss Ratings upgraded Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Wall Street Zen downgraded Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Oncolytics Biotech Stock Performance

NASDAQ:ONCY opened at $0.90 on Thursday. The company has a market capitalization of $107.42 million, a price-to-earnings ratio of -2.90 and a beta of 1.02. Oncolytics Biotech has a one year low of $0.33 and a one year high of $1.51. The stock has a 50-day simple moving average of $0.93 and a 200 day simple moving average of $0.98.

Oncolytics Biotech (NASDAQ:ONCY) last announced its earnings results on Thursday, May 14th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03).

Hedge Funds Weigh In On Oncolytics Biotech

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Scientech Research LLC acquired a new position in Oncolytics Biotech in the third quarter valued at approximately $25,000. Blair William & Co. IL acquired a new position in Oncolytics Biotech in the fourth quarter valued at approximately $28,000. Security National Bank of Sioux City Iowa IA acquired a new position in Oncolytics Biotech in the fourth quarter valued at approximately $29,000. Ground Swell Capital LLC acquired a new position in Oncolytics Biotech in the fourth quarter valued at approximately $30,000. Finally, CIBC Private Wealth Group LLC acquired a new position in Oncolytics Biotech in the fourth quarter valued at approximately $44,000. 6.82% of the stock is currently owned by institutional investors and hedge funds.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.